Monthly Archives: noviembre 2017

Stem Cells Transl Med. 2017 Oct;6(10):1930-1939. doi: 10.1002/sctm.17-0054 Age-related (type-II) osteoporosis is a common and debilitating condition driven in part by the loss of bone marrow (BM) mesenchymal stromal cells (MSC) and their osteoblast progeny, leading to reduced bone formation. Current pharmacological regiments targeting age-related osteoporosis do not directly treat the disease by increasing bone […]

Diabetes Res Clin Pract. 2017 Oct 18;134:153-160. doi:10.1016/j.diabres.2017.10.011 AIMS: To determine the relative risk of incident hip fracture in patients with type 1 diabetes and matched controls and to compare hip fracture rates in age- and sex-matched patients with type 1 versus type 2 diabetes. METHODS: Longitudinal observational study of 121 adults with type 1 […]

Bone. 2018 Jan;106:22-27. doi: 10.1016/j.bone.2017.10.005 Sarcopenia and osteoporosis are among the late complications of type 1 diabetes (T1D) in adults. The aim of this study was to assess volumetric bone mineral density (BMD) and dynamic muscle function in adolescents with T1D and to assess the clinical and biochemical predictors of their musculoskeletal system. METHODS: Ninety-five […]

J Bone Miner Res. 2017 Nov 4. doi: 10.1002/jbmr.3337 Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk. Denosumab discontinuation increases BTMs 3 months after a scheduled dose is omitted, reaching above-baseline levels by 6 months, and decreases BMD to baseline levels by 12 months. We analyzed the risk of new or worsening vertebral […]

Bone. 2017 Oct;103:159-167. doi: 10.1016/j.bone.2017.06.027 Parathyroid hormone (PTH) and Notch receptors regulate bone formation by governing the function of osteoblastic cells. To determine whether PTH interacts with Notch signaling as a way to control osteoblast function, we tested the effects of PTH on Notch activity in osteoblast- and osteocyte-enriched cultures. Induction of Notch signaling in […]